5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies

Authors :: Catherine Thieblemont
K. Yee
Xavier Thomas
Norbert Vey
Emanuele Zucca
Claude Preudhomme
C. Recher
Y. Peng
Carlos Gomez-Roca
L. Karlin
Hervé Dombret
Patrice Herait
Keyvan Rezai
Anastasios Stathis
Mauricette Michallet
Sandy Amorim
T. Facon
B. Quesnel
Antonio Palumbo
Emmanuel Raffoux
Source :: European Journal of Cancer. 50:196
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: Cancer Research
Oncology
business.industry
Cancer research
Medicine
business
Bromodomain

Tools